252 related articles for article (PubMed ID: 9440758)
21. Expression of multidrug resistance-associated protein1,P-glycoprotein, and thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection.
Choi JH; Lim HY; Joo HJ; Kim HS; Yi JW; Kim HC; Cho YK; Kim MW; Lee KB
Br J Cancer; 2002 May; 86(10):1578-85. PubMed ID: 12085207
[TBL] [Abstract][Full Text] [Related]
22. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin.
Leichman CG; Lenz HJ; Leichman L; Danenberg K; Baranda J; Groshen S; Boswell W; Metzger R; Tan M; Danenberg PV
J Clin Oncol; 1997 Oct; 15(10):3223-9. PubMed ID: 9336359
[TBL] [Abstract][Full Text] [Related]
23. ERCC1 expression and chemosensitivity in uterine cervical adenocarcinoma cells.
Torii Y; Kato R; Minami Y; Hasegawa K; Fujii T; Udagawa Y
Anticancer Res; 2014 Jan; 34(1):107-15. PubMed ID: 24403450
[TBL] [Abstract][Full Text] [Related]
24. Comprehensive analysis of excision repair complementation group 1, glutathione S-transferase, thymidylate synthase and uridine diphosphate glucuronosyl transferase 1A1 polymorphisms predictive for treatment outcome in patients with advanced gastric cancer treated with FOLFOX or FOLFIRI.
Seo BG; Kwon HC; Oh SY; Lee S; Kim SG; Kim SH; Han H; Kim HJ
Oncol Rep; 2009 Jul; 22(1):127-36. PubMed ID: 19513514
[TBL] [Abstract][Full Text] [Related]
25. Clinicopathologic significance of ERCC1, thymidylate synthase and glutathione S-transferase P1 expression for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy.
Kim KH; Kwon HC; Oh SY; Kim SH; Lee S; Kwon KA; Jang JS; Kim MC; Kim SJ; Kim HJ
Biomarkers; 2011 Feb; 16(1):74-82. PubMed ID: 21133646
[TBL] [Abstract][Full Text] [Related]
26. Relationship between TYMS and ERCC1 mRNA expression and in vitro chemosensitivity in colorectal cancer.
Cho YB; Chung HJ; Lee WY; Choi SH; Kim HC; Yun SH; Chun HK
Anticancer Res; 2011 Nov; 31(11):3843-9. PubMed ID: 22110208
[TBL] [Abstract][Full Text] [Related]
27. High pretherapeutic thymidylate synthetase and MRP-1 protein levels are associated with nonresponse to neoadjuvant chemotherapy in oesophageal adenocarcinoma patients.
Langer R; Ott K; Feith M; Lordick F; Specht K; Becker K; Hofler H
J Surg Oncol; 2010 Oct; 102(5):503-8. PubMed ID: 20589706
[TBL] [Abstract][Full Text] [Related]
28. Changes in intratumoral thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) mRNA expression in colorectal and gastric cancer during continuous tegafur infusion.
Uchida K; Hayashi K; Kuramochi H; Takasaki K
Int J Oncol; 2001 Aug; 19(2):341-6. PubMed ID: 11445849
[TBL] [Abstract][Full Text] [Related]
29. Thymidylate synthase and dihydropyrimidine dehydrogenase are related to histological effects of 5-fluorouracil and cisplatin neoadjuvant chemotherapy for primary gastric cancer patients.
Fukuda H; Takiguchi N; Koda K; Oda K; Seike K; Miyazaki M
Cancer Invest; 2006; 24(3):235-41. PubMed ID: 16809149
[TBL] [Abstract][Full Text] [Related]
30. [The intratumoral levels of thymidylate synthetase and folate in gastric and colon cancer].
Iba T; Yagi Y; Kidokoro A; Ishi K; Koyatsu J
Gan To Kagaku Ryoho; 1998 Jul; 25(8):1165-71. PubMed ID: 9679579
[TBL] [Abstract][Full Text] [Related]
31. Polymorphisms in ERCC1, GSTs, TS and MTHFR predict clinical outcomes of gastric cancer patients treated with platinum/5-Fu-based chemotherapy: a systematic review.
Wang Z; Chen JQ; Liu JL; Qin XG; Huang Y
BMC Gastroenterol; 2012 Sep; 12():137. PubMed ID: 23020798
[TBL] [Abstract][Full Text] [Related]
32. Detection of cell-free ERCC1 and thymidylate synthase (TS) mRNA in malignant effusions and its association with anticancer drug sensitivity.
Wang L; Liu B; Wang T; Ding Y; Qian X; Zhao Y
Anticancer Res; 2008; 28(2A):1085-91. PubMed ID: 18507058
[TBL] [Abstract][Full Text] [Related]
33. Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin.
Zucali PA; Giovannetti E; Destro A; Mencoboni M; Ceresoli GL; Gianoncelli L; Lorenzi E; De Vincenzo F; Simonelli M; Perrino M; Bruzzone A; Thunnissen E; Tunesi G; Giordano L; Roncalli M; Peters GJ; Santoro A
Clin Cancer Res; 2011 Apr; 17(8):2581-90. PubMed ID: 21262916
[TBL] [Abstract][Full Text] [Related]
34. Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)--novel predictors for response and survival in gastric cancer patients.
Goekkurt E; Hoehn S; Wolschke C; Wittmer C; Stueber C; Hossfeld DK; Stoehlmacher J
Br J Cancer; 2006 Jan; 94(2):281-6. PubMed ID: 16317430
[TBL] [Abstract][Full Text] [Related]
35. Bax predicts outcome in gastric cancer patients treated with 5-fluorouracil, leucovorin, and oxaliplatin palliative chemotherapy.
Jeong SH; Han JH; Kim JH; Ahn MS; Hwang YH; Lee HW; Kang SY; Park JS; Choi JH; Lee KJ; Sheen SS; Lim HY
Dig Dis Sci; 2011 Jan; 56(1):131-8. PubMed ID: 20503071
[TBL] [Abstract][Full Text] [Related]
36. Thymidylate synthetase (TS) genotype and TS/dihydropyrimidine dehydrogenase mRNA level as an indicator in determining chemosensitivity to 5-fluorouracil in advanced gastric carcinoma.
Toriumi F; Kubota T; Saikawa Y; Yoshida M; Otani Y; Watanabe M; Kumai K; Kitajima M
Anticancer Res; 2004; 24(4):2455-63. PubMed ID: 15330198
[TBL] [Abstract][Full Text] [Related]
37. Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma.
Lee S; Park YH; Kim KH; Cho EY; Ahn YC; Kim K; Shim YM; Ahn JS; Park K; Im YH
Br J Cancer; 2010 Sep; 103(6):845-51. PubMed ID: 20700125
[TBL] [Abstract][Full Text] [Related]
38. ERCC1 polymorphism, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in gastric cancer.
Huang ZH; Hua D; Du X; Li LH; Mao Y; Liu ZH; Song MX; Zhou XK
World J Gastroenterol; 2008 Nov; 14(41):6401-7. PubMed ID: 19009659
[TBL] [Abstract][Full Text] [Related]
39. Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer.
Schneider S; Uchida K; Brabender J; Baldus SE; Yochim J; Danenberg KD; Salonga D; Chen P; Tsao-Wei D; Groshen S; Hoelscher AH; Schneider PM; Danenberg PV
J Am Coll Surg; 2005 Mar; 200(3):336-44. PubMed ID: 15737843
[TBL] [Abstract][Full Text] [Related]
40. [ERCC1 and TS expression in chemoradiotherapy treated esophageal squamous cell carcinoma].
Sobajima J; Haga N; Kumamoto K; Ishibashi K; Ishida H
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2394-6. PubMed ID: 21224584
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]